Frank Witney, Paul Keim, Trilochan Sahoo, Jack Lord, Mari Baker, Patrick Terry, Lutz Kirchrath
NextBio will use the funds to develop its vertebrate and plant information platform for cross-species research.
The merger will combine Eureka's bioinformatics capabilities with Nanobac's drug discovery program focused on inhibiting, destroying, or neutralizing calcifying nanoparticles.
Some of NIH's and NHGRI's challenge grants will give priorities to ethical issues that confront genomics, pharmacogenomics, and biomedicine.
Verdezyne will optimize selected genes that encode industrial enzymes for Novozymes.
Complete Genomics has been forced to cut staff salaries and take other cost-saving steps as its Series D financing round has been delayed in closing.
Developing high-throughput technologies, personalized medicine, and data handling tools are the focus of the NIH/NHGRI challenge grants.
The companies have partnered to integrate the Geneus software for use with ABI's next-generation sequencing system.
Nearly $14 million next year will support centers to study malaria and develop gene-based diagnostics.
The approximately $17 million acquisition, announced last week, will have "no impact" on Clinical Data's focus as a pharmacogenomics company, according to CEO Drew Fromkin.
The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.
The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.
New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.
In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.